Caixin
BUSINESS & TECH

China Expected to Approve Several Foreign Blockbuster Drugs in 2018

A new report says that a spate of expected drug approvals in China will pave the way for the drugmakers to further expand in one of the world’s largest drug markets. Photo: Visual China
A new report says that a spate of expected drug approvals in China will pave the way for the drugmakers to further expand in one of the world’s largest drug markets. Photo: Visual China

Foreign pharmaceutical giants Bristol-Myers Squibb, Novartis and AstraZeneca will win approval for some of their star products from China’s drug regulator in 2018, drug data provider PharmCube predicted in a recent report.

The approvals will pave the way for the drugmakers to further expand in one of the world’s largest drug markets, the report said.

Bristol-Myers’ cancer injection nivolumab is expected to be greenlighted in the first quarter, as China’s Center for Drug Evaluation began reviewing it in November, according to the report by the Beijing-based PharmCube.

ladingImg
You've accessed an article available only to subscribers
Try 4 weeks for $0.99
SUBSCRIBE
Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.